Intellia Secures $400M Non-Dilutive Debt Facility with OrbiMed

summarizeSummary

Intellia closed a $400M non-dilutive senior secured term loan with OrbiMed, drawing $75M upfront with the rest tied to lonvo-z milestones. The facility is secured by substantially all assets including IP and carries restrictive covenants.

check_boxKey Events · Financing and Capital Events · NTLA

• $400M Credit Facility Closed

  Intellia entered a five-year senior secured credit facility with OrbiMed for up to $400M, with $75M drawn at closing on September 4, 2026.

• Milestone-Based Tranche Structure

  Additional draws include $75M upon FDA approval of lonvo-z BLA, three $40M draws tied to revenue targets, $30M tied to an equity raise, and an uncommitted $100M incremental facility.

• Interest and Maturity Terms

  Loans bear interest at the greater of 3.00% or one-month SOFR plus 6.15% margin, payable monthly, maturing September 4, 2031.

• Security and Covenants

  Obligations are secured by a first-priority lien on substantially all assets including intellectual property. Covenants require maintaining at least $50M in controlled accounts until FDA approval of lonvo-z BLA.

auto_awesomeAnalysis · NTLA · Life Sciences

Intellia closed a $400 million senior secured credit facility with OrbiMed, drawing $75 million upfront. The remaining $325 million is tied to milestones including FDA approval of lonvo-z, revenue targets, and an equity raise. This non-dilutive financing extends Intellia's cash runway without issuing shares, but comes with a first-priority lien on substantially all assets including intellectual property, restrictive covenants, and a liquidity floor of $50 million until BLA approval. The interest rate of SOFR + 6.15% (floor 9.15%) reflects the risk profile of a pre-commercial biotech.